An effort to examine the feasibility of whole exome and transcriptome sequencing in guiding personalized therapy for patients with non-small cell lung cancer.

e19136 Background: Usefulness of the next-generation sequencing in clinical practice for cancer treatment is in early development. We sought to evaluate the feasibility of clinical application of whole exome sequencing (WES) or whole exome plus transcriptome sequencing (WETS) to provide guidance for personalized therapy. Methods: Tumor samples and clinical information of 15 patients who were diagnosed with non-small cell lung cancer (NSCLC) were collected. Sequencing and bioinformatics analysis were then performed by BGI-Shenzhen to detect the genomic alterations and changes in RNA expressions. Interpretation was performed base on systematic review of publications that report the relationship between specific genomic alterations/gene expression level and the sensitivity/toxicity of the anticancer drugs. All agents involved in the interpretation were classified by FDA approval status and, subsequently, NCCN recommendations for NSCLC or other cancers. Results: All patients were analyzed for WES with 10 pati...